Cambridge Epigenetix (CEGX) has appointed epigenetics-based therapeutics specialist professor Mark Dawson to its Scientific Advisory Board (SAB). Mark is professor in the Sir Peter MacCallum Department of Oncology and Centre for Cancer Research at the University of Melbourne, where he is the program head of the Translational Haematology Program, group leader of the Cancer Epigenetics Laboratory and consultant haematologist in the Department of Haematology.
